《2023年美国肝病学会实践指南:肝细胞癌预防、诊断和治疗》要点摘译  

Excerpt from the 2023 American Association for the Study of Liver Diseases practice guideline:prevention,diagnosis,and treatment of hepatocellular carcinoma

作　　者：王钲钰 夏冬东 韩国宏 Wang Zhengyu;Xia Dongdong;Han Guohong(Department of Digestive and Peripheral Vascular Interventional Radiology,Xi’an International Medical Center Hospital,Xi’an 710100,China)

机构地区：[1]西安国际医学中心医院消化与外周血管介入科,西安710100

出　　处：《中华肝脏病杂志》2023年第12期1262-1265,共4页Chinese Journal of Hepatology

摘　　要：《2023年美国肝病学会实践指南:肝细胞癌预防、诊断和治疗》(简称指南)提供了肝细胞癌(HCC)的预防、诊断和治疗的最新方法。为反映HCC多个领域具有临床意义的重大进展,指南在既往美国肝病学会(AASLD)HCC指南的基础上进行了更新。更新的显著案例包括推荐使用超声和甲胎蛋白进行HCC监测,扩大手术治疗的适应证,将免疫抑制剂治疗纳入一线全身治疗,以及明确推荐多学科诊疗和预立医疗自主计划。The 2023 American Association for the Study of Liver Diseases practice guidelines(hereinafter referred to as the Guidelines)provide the latest approach for the prevention,diagnosis,and treatment of hepatocellular carcinoma.The prior American Association for the study of Liver Diseases(AASLD)HCC guidelines have been updated to reflect the clinically significant advances in multiple fields of HCC.Notable examples of these updates include recommendations for the use of ultrasound and alpha-fetoprotein for HCC monitoring,the expansion of surgical treatment indications,the addition of immunosuppressive therapy as first-line systemic therapy,and the implementation of clear multidisciplinary care and proactive care planning.

关 键 词：肝细胞癌 指南 管理 筛查 治疗 

分 类 号：R735.7[医药卫生—肿瘤]